​

GeneDx (WGS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

GeneDx Revenue Highlights

Latest Revenue (Y)

$427.54M

Latest Revenue (Q)

$116.74M

Main Segment (Y)

Diagnostic Test

Main Geography (Y)

Other

GeneDx Revenue by Period

GeneDx Revenue by Year

DateRevenueChange
2025-12-31$427.54M39.97%
2024-12-31$305.45M50.79%
2023-12-31$202.57M-13.69%
2022-12-31$234.69M10.60%
2021-12-31$212.19M18.33%
2020-12-31$179.32M-8.59%
2019-12-31$196.17M-

GeneDx generated $427.54M in revenue during NA 2025, up 39.97% compared to the previous quarter, and up 238.42% compared to the same period a year ago.

GeneDx Revenue by Quarter

DateRevenueChange
2025-09-30$116.74M13.68%
2025-06-30$102.69M17.88%
2025-03-31$87.11M-8.91%
2024-12-31$95.64M24.41%
2024-09-30$76.87M9.02%
2024-06-30$70.51M12.96%
2024-03-31$62.42M8.72%
2023-12-31$57.42M7.72%
2023-09-30$53.30M9.44%
2023-06-30$48.71M12.90%
2023-03-31$43.14M-29.68%
2022-12-31$61.35M-26.29%
2022-09-30$83.23M130.13%
2022-06-30$36.17M-32.95%
2022-03-31$53.94M-6.68%
2021-12-31$57.80M33.87%
2021-09-30$43.18M-7.87%
2021-06-30$46.87M-27.00%
2021-03-31$64.20M0.38%
2020-12-31$63.96M65.66%
2020-09-30$38.61M-

GeneDx generated $116.74M in revenue during Q3 2025, up 13.68% compared to the previous quarter, and up 165.56% compared to the same period a year ago.

GeneDx Revenue Breakdown

GeneDx Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 22
Diagnostic Test$416.67M$302.16M$227.33M
Diagnostic Test, Institutional Customers$70.07M$65.11M-
Diagnostic Test, Self Pay$1.36M$2.34M-
Diagnostic Test, Third Party Insurance$345.24M$234.70M-
Product and Service, Other$10.87M$3.29M$7.36M

GeneDx's latest annual revenue breakdown by segment (product or service), as of Dec 25: Diagnostic Test (49.36%), Diagnostic Test, Third Party Insurance (40.89%), Diagnostic Test, Institutional Customers (8.30%), Product and Service, Other (1.29%), and Diagnostic Test, Self Pay (0.16%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Diagnostic Test, Self Pay$297.00K$629.00K$339.00K$96.00K$1.19M$460.00K$692.00K
Diagnostic Test$117.56M$113.52M$99.82M$85.76M$155.30M$77.42M$69.44M
Diagnostic Test, Institutional Customers$16.21M$17.87M$18.38M$17.60M$31.00M$17.41M$16.70M
Product and Service, Other$3.43M$3.22M$2.87M$1.36M$2.76M$-544.00K$1.07M
Diagnostic Test, Third Party Insurance$101.05M$95.02M$81.10M$68.06M$123.10M$59.54M$52.05M

GeneDx's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Diagnostic Test (49.28%), Diagnostic Test, Third Party Insurance (42.36%), Diagnostic Test, Institutional Customers (6.80%), Product and Service, Other (1.44%), and Diagnostic Test, Self Pay (0.12%).

GeneDx Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 24
Other$3.16M

GeneDx's latest annual revenue breakdown by geography, as of Dec 24: Other (100.00%).

GeneDx Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
OSCROscar Health$11.70B$2.99B
OPCHOption Care Health$5.65B$1.44B
PRVAPrivia Health Group$2.12B$580.42M
TMDXTransMedics Group$605.49M$143.82M
HNGEHinge Health$587.86M$154.21M
WGSGeneDx$427.54M$116.74M
KYMRKymera Therapeutics$39.20M$2.76M
NAMSNewAmsterdam Pharma$22.50M$19.14M
CRNXCrinetics Pharmaceuticals$5.42M$143.00K
VKTXViking Therapeutics--
IMVTImmunovant--

WGS Revenue FAQ

What is GeneDx’s yearly revenue?

GeneDx's yearly revenue for 2025 was $427.54M, representing an increase of 39.97% compared to 2024. The company's yearly revenue for 2024 was $305.45M, representing an increase of 50.79% compared to 2023. WGS's yearly revenue for 2023 was $202.57M, representing a decrease of -13.69% compared to 2022.

What is GeneDx’s quarterly revenue?

GeneDx's quarterly revenue for Q3 2025 was $116.74M, a 13.68% increase from the previous quarter (Q2 2025), and a 51.86% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $102.69M, a 17.88% increase from the previous quarter (Q1 2025), and a 45.63% increase year-over-year (Q2 2024). WGS's quarterly revenue for Q1 2025 was $87.12M, a -8.91% decrease from the previous quarter (Q4 2024), and a 39.56% increase year-over-year (Q1 2024).

What is GeneDx’s revenue growth rate?

GeneDx's revenue growth rate for the last 3 years (2023-2025) was 111.06%, and for the last 5 years (2021-2025) was 101.48%.

What are GeneDx’s revenue streams?

GeneDx's revenue streams in c 25 are Diagnostic Test, Diagnostic Test, Institutional Customers, Diagnostic Test, Self Pay, Diagnostic Test, Third Party Insurance, and Product and Service, Other. Diagnostic Test generated $416.67M in revenue, accounting 49.36% of the company's total revenue, up 37.90% year-over-year. Diagnostic Test, Institutional Customers generated $70.07M in revenue, accounting 8.30% of the company's total revenue, up 7.61% year-over-year. Diagnostic Test, Self Pay generated $1.36M in revenue, accounting 0.16% of the company's total revenue, down -41.91% year-over-year. Diagnostic Test, Third Party Insurance generated $345.24M in revenue, accounting 40.89% of the company's total revenue, up 47.10% year-over-year. Product and Service, Other generated $10.87M in revenue, accounting 1.29% of the company's total revenue, up 230.12% year-over-year.

What is GeneDx’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of GeneDx was Diagnostic Test. This segment made a revenue of $416.67M, representing 49.36% of the company's total revenue.